Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Tapas K. Pradhan"'
Autor:
Tapas K. Pradhan1, Wayne E. Criss1
Publikováno v:
European Journal of Biochemistry. Apr74 Part 2, Vol. 43 Issue 3, p541-547. 7p.
Autor:
Terry W. Moody, Nieves González, Tapas K. Pradhan, Samuel A. Mantey, Robert T. Jensen, David H. Coy, Veronica Sancho
Publikováno v:
Peptides. 30:1473-1486
The mammalian Bombesin (Bn) peptides neuromedin B (NMB) and gastrin-releasing peptide (GRP) actions are mediated by two receptors (NMB-receptor, GRP-receptor) which are widely distributed in the GI tract and CNS. From primarily animal studies NMB/GRP
Autor:
Lin Shen, Tapas K. Pradhan, Nieves González, Michael Schumann, Robert T. Jensen, David H. Coy, Samuel A. Mantey
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 319:980-989
Mammalian bombesin (Bn) receptors include the gastrin-releasing peptide receptor, neuromedin B receptor, and bombesin receptor subtype 3 (BRS-3). These receptors are involved in a variety of physiological/pathologic processes, including thermoregulat
Autor:
Tapas K. Pradhan, Joseph A. Fuselier, Robert T. Jensen, Samuel A. Mantey, David H. Coy, Terry W. Moody, Tomoo Nakagawa
Publikováno v:
Peptides. 26:1560-1566
The effects of camptothecin-somatostatin (CPT-SS) conjugates were investigated on small cell lung cancer (SCLC) cells. CPT was coupled to a SS agonist (SSA), c(Cys-Phe-DTrp-Lys-Thr-Cys)Thr-NH2 using the built in nucleophile assisted-releasing group (
Autor:
Tapas K. Pradhan, Hisato Igarashi, David H. Coy, Tetsuhide Ito, Wei Hou, Robert T. Jensen, Samuel A. Mantey
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 315:370-381
Vasoactive intestinal peptide (VIP) is a widespread neurotransmitter whose physiological and pathophysiological actions are mediated by two receptor classes, VIP/pituitary adenylate cyclase-activating polypeptide (VPAC) 1 and VPAC2. VIP is a 28-amino
Autor:
Michael Schumann, David H. Coy, Tapas K. Pradhan, Samuel A. Mantey, Terry W. Moody, Alfredo Martínez, Robert T. Jensen, Tomoo Nakagawa, Joseph A. Fuselier
Publikováno v:
Journal of Biological Chemistry. 279:23580-23589
Mammalian bombesin (BN) receptors are among those most frequently overexpressed by a number of common tumors including prostate, breast, lung, and colon cancers. The aim of this study was to develop a camptothecin-bombesin (CPT-BN) conjugate that int
Autor:
Robert T. Jensen, Tetsuhide Ito, David H. Coy, Simon J. Hocart, Charles D. Ulrich, Samuel A. Mantey, Tapas K. Pradhan, Hisato Igarashi, Wei Hou
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 301:37-50
Vasoactive intestinal peptide (VIP) is a neurotransmitter involved in a number of pathological and physiological processes. VIP is rapidly degraded and simplified stable analogs are needed. VIP's action was extensively studied in rat and guinea pig.
Autor:
Robert T. Jensen, Tetsuhide Ito, David H. Coy, John E. Taylor, William A. Murphy, Hisato Igarashi, Samuel A. Mantey, Tapas K. Pradhan, Wei Hou
Publikováno v:
Peptides. 22:1139-1151
Growth hormone (GH) is used or is being evaluated for efficacy in treatment of short stature, aspects of aging, cardiac disorders, Crohn's disease, and short bowel syndrome. Therefore, we synthesized several stable growth hormone-releasing factor (GR
Autor:
Tapas K. Pradhan, Tatsuro Katsuno, D. H. Coy, Mark A. Akeson, R.R. Ryan, Wei Hou, James F. Battey, Patrick J. Donohue, Eliot R. Spindel, Robert T. Jensen, Samuel A. Mantey
Publikováno v:
Biochemistry. 38:7307-7320
Recently, a fourth member of the bombesin (Bn) receptor family (fBB4-R) was isolated from a cDNA library from the brain of the frog, Bombina orientalis. Its pharmacology and cell biology are largely unknown, and no known natural cell lines or tissues
Autor:
Eduardo Sainz, R.R. Ryan, Robert T. Jensen, Tapas K. Pradhan, James F. Battey, H. Christian Weber, Samuel A. Mantey, David H. Coy, Mark A. Akeson, Eliot R. Spindel, Robert P. Searles
Publikováno v:
Journal of Biological Chemistry. 272:26062-26071
An orphan receptor discovered in 1993 was called bombesin receptor subtype 3 (BRS-3) because of 47-51% amino acid identity with bombesin (Bn) receptors. Its pharmacology is unknown, because no naturally occurring tissues have sufficient receptors to